G

ood morning, everyone. STAT reporter Rebecca Robbins here, filling in to serve up your breakfast buffet of headlines from the world of pharma. Another week has nearly come and gone, which means it’s time to daydream about the weekend and its assorted respites. Do be certain to relax, and try to have fun, and stay safe, whatever it is you end up doing. Until then, send us a note if you hear anything that warrants a spot in these digital pages.

Lawmakers have some questions for Merck (MRK) about how a cyberattack in June roiled its operations, including whether it hit the company’s supplies of the hepatitis B vaccine, Endpoints tells us. In a letter to Merck sent this week, the House Committee on Energy and Commerce requested a formal briefing from the company by October 4.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy